ASH 2012 Report – New results support bendamustine-rituximab (B-R) combination as first-line treatment in patients with (iNHL) and (MCL)
Data demonstrate superior patient outcomes with B-R in first-line treatment of iNHL and MCL, compared with current standard of care.